NASDAQ •
Healthcare •
Biotechnology •
Quote as of 05/13/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization5,915.93 mln
Float29.66 mln
Earnings Date05/14/2026
Piotroski F-Score
2
/ 9
Weak
1-Year Forecast
160
Strong upside
Relative Strength
71
/ 100
Outperforming
Debt / Equity
3.20
Highly leveraged
ROE
-191
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Celcuity is a Minneapolis-based clinical-stage company founded in 2011 that develops precision treatments for solid tumors. Its primary focus is Gedatolisib, a drug designed to block key molecular pathways that drive advanced breast cancer and metastatic prostate cancer. The company holds a licensing agreement with Pfizer covering the development and commercialization of this drug candidate.
